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Does type 1 diabetes mellitus affect
Achilles tendon response to a 10 km run?
A case control study
Andrea M. Y. Wong1*, Sean I. Docking1,2,3, Jill L. Cook1,2,3 and James E. Gaida1,4,5
Abstract
Background: Achilles tendon structure deteriorates 2-days after maximal loading in elite athletes. The load-response
behaviour of tendons may be altered in type 1 diabetes mellitus (T1DM) as hyperglycaemia accelerates collagen
cross-linking. This study compared Achilles tendon load-response in participants with T1DM and controls.
Methods: Achilles tendon structure was quantified at day-0, day-2 and day-4 after a 10 km run. Ultrasound tissue
characterisation (UTC) measures tendon structural integrity by classifying pixels as echo-type I, II, III or IV. Echo-type I
has the most aligned collagen fibrils and IV has the least.
Results: Participants were 7 individuals with T1DM and 10 controls. All regularly ran distances greater than 5 km
and VISA-A scores indicated good tendon function (T1DM = 94 ± 11, control = 94 ± 10). There were no diabetic
complications and HbA1c was 8.7 ± 2.6 mmol/mol for T1DM and 5.3 ± 0.4 mmol/mol for control groups. Baseline
tendon structure was similar in T1DM and control groups – UTC echo-types (I-IV) and anterior-posterior thickness
were all p > 0.05. No response to load was seen in either T1DM or control group over the 4-days post exercise.
Conclusion: Active individuals with T1DM do not have a heightened Achilles tendon response to load, which
suggests no increased risk of tendon injury. We cannot extrapolate these findings to sedentary individuals
with T1DM.
Keywords: Exercise, Imaging, T1DM, Achilles, Tendon
Background
Diabetes mellitus (DM) is a group of chronic metabolic
disorders characterised by inappropriate levels and/or
utilisation of the hormone insulin, leading to elevated
blood glucose concentrations. Hyperglycaemia contrib-
utes to long-term health complications that increase
morbidity and mortality [1, 2]. Type 1 diabetes mellitus
(T1DM) is the result of a complex autoimmune re-
sponse that destroys insulin-producing β-cells in the
pancreas.
Individuals with T1DM use exogenous insulin injec-
tions to maintain glycaemic control [3]. Glycaemic
control can be measured through haemoglobin A1c
(HbA1c), which is generated by glucose mediated
cross-linking of normal haemoglobin. Cross-linking
occurs at a faster rate at high glucose levels, and
therefore, HbA1c is a useful measure of glycaemic
control that reflects average blood glucose concentra-
tions over the previous 2–3 months [4, 5]. Maintain-
ing tight glucose control to achieve HbA1c levels less
than 7 % (53 mmol/mol) decreases the risk of microvascu-
lar and macrovascular complications of diabetes such a
retinopathy, nephropathy, neuropathy and macrovascular
complications [6–10].
Soft tissue thickening due to accelerated cross-linking
of collagen is a common diabetic complication [11–13].
Tendons are susceptible to accelerated crosslinking and
therefore pathological changes. This concept is sup-
ported by data from a recent systematic review, which
identified greater prevalence of DM in those with tendi-
nopathy compared to controls without tendinopathy. A
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higher prevalence of tendinopathy was also seen in
those with DM compared to controls without DM [14].
Studies that pooled T1DM and T2DM data found a
significant increase in Achilles tendon thickness in
DM participants compared to controls on ultrasound
imagining [15, 16], however there were no T1DM spe-
cific data.
The prevalence of T1DM among individuals with
Achilles tendinopathy – based on GP diagnosis codes
in electronic records – is 1.8 % (95 % confidence
interval = 0 to 4.5) and therefore not significantly dif-
ferent from the point estimate for the Dutch popula-
tion (0.8 %) [17]. Results of the systematic review
found there was a complete absence of data on
tendon structure in people with T1DM [18]. Under-
standing tendon integrity and response to load in the
T1DM population is important, as physical activity is
a key component of long-term metabolic control of
T1DM [19] and musculoskeletal injury frequently
prevents physical activity [20]. Furthermore, increased
Achilles tendon thickness in conjunction with in-
creased plantar fascia thickness and neuropathy has
been associated with altered timing in onset and duration
of the windlass mechanism during gait [15, 16, 21].
This can reduce the capacity of the foot to absorb
shock, as it is rigid for a greater part of the gait cycle
[15, 16].
This study aims to determine whether the Achilles
tendon of T1DM individuals has the same response to a
10 km run compared to non-diabetic controls. This will
be measured using ultrasound tissue characterisation
(UTC) [22], as it can measure transient response in ten-
don alignment at day 2 post maximal competitive load,
which then returns to baseline by day 4 [23, 24].
Subjects
Study design
A case–control design was used in the setting of a T1DM
social running club.
Participants
Participants were members and friends/family of HypoAc-
tive running club, a not-for-profit organisation that aims
to inspire and enable individuals with T1DM to live a
physically active lifestyle. Participants were excluded if
they had: a previous Achilles tendon rupture; used medi-
cation known to affect tendons in the previous 3 months
(e.g. fluroquinolone antibiotics, corticosteroids); inflam-
matory conditions such as ankylosing spondylitis, rheuma-
toid arthritis and related conditions; or were under the
age of 18. Control participants were excluded based on
the criteria above and if they had a diagnosis of diabetes
mellitus (T1DM or T2DM).
Methods
Outcome measures
Participants had their left Achilles tendon scanned with
UTC before the 10 km run, and 2 and 4 days after the
run. Participants stood on an elevated box with their
great toe and knee touching a wall. The tracking device
(UTC tracker, UTC imaging) with a 7–10 MHz linear
ultrasound probe (SmartProbe 10 L5, Terason 2000;
Teratech) was placed on the posterior calcaneal region
and positioned parallel to the long axis of the Achilles
tendon. The data acquisition sequence captures trans-
verse ultrasound images every 0.2 mm along 12 cm
length of the tendon (UTC software, UTC imaging). The
3D data-block is assembled and UTC algorithms are
used to quantify echopatterns over a rolling window of
25 continuous images (4.8 mm). The analysis was per-
formed from the disappearance of the calcaneum to the
musculotendinous junction. UTC quantifies the struc-
tural integrity of a tendon by comparing the stability of
pixel brightness over contiguous transverse images and
classifies them into four echo-types [22]. Echo-type I re-
flects homogeneity of tendon fibrils within the tendon
matrix, and echo-types II, III and IV represent increasing
variability in the alignment of tendon fibrils [22]. UTC is
reliable in both equine [23] and human [24] tendons and
has been validated against pathological tendons histolog-
ically [25–27]. The minimum detectable difference in
the Achilles tendon is 0.9 % for echo-type I, 0.9 % for
echo-type II, 0.3 % for echo-type III and 0.6 % for echo-
type IV [24].
All UTC scans were conducted by one investigator
(AW). A second investigator (SD) relabelled the scan
data using random numbers so that the investigator per-
forming the analysis (AW) was blinded to group and
time. In addition, anterior-posterior (AP) diameter was
calculated 2 cm proximal from the disappearance of the
calcaneum.
All participants were tested for blood glucose level
(BGL) using a glucometer (Optimum Xceed, Abbott Dia-
betes Care Inc., Alameda, CA, USA), and for HbA1c using
a batch-validated HbA1c test cartridge (DCA Vantage,
Siemens Medical Solutions Diagnostics, Tarrytown, NY,
USA) [28].
Each participant completed a questionnaire on current
and past medical history, physical activity level and ten-
don pain and/or injury history. The questionnaire also
obtained information on the covariates of age, gender,
duration of diabetes and diabetic complications. Partici-
pants also completed the VISA-A questionnaire, which
provides an index of the severity of Achilles tendon pain
and function on a scale of 0–100, where 100 indicates
no pain or loss of function [29]. The VISA-A question-
naire has been shown to be reliable with good test-retest
(r = 0.93), intra-rater (3 test, r = 0.90) and inter-rater
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(r = 0.90) reliability, as well as good stability when
compared one week apart (r = 0.81) [29].
Height (nearest 0.1 cm) and body mass (nearest 0.1
kg) were measured to calculate body mass index (BMI),
and waist circumference was measure to the nearest 0.1
cm. Average run speed was calculated and participants
were asked to refrain from additional running during the
4-day study.
Analyses
All four UTC echo-types were analysed for normality
using a Kolmogorov-Smirnov test. As the UTC data
were not normally distributed, the analysis used non-
parametric statistics and data are reported as median
and interquartile range. Differences in the four echo-
types and AP diameter between the two groups at day 0
were determined using an independent-samples Mann–
Whitney U test. Differences across day 0, 2 and 4 me-
dians were analysed within each group using a related-
samples Friedman’s test.
Spearman’s correlation was used to determine whether
an association existed between proxy measures of gly-
caemic control (BGL and HbA1c) and echo-type I (day 0).
Analysis was limited to echo-type I in order to limit the
possibility of type 1 statistical errors. All analyses were
performed using statistical software (IBM SPSS Statistics
version 20), with an alpha level set at 0.05.
Ethics
Ethics approval was obtained by the Monash University
Human Research Ethics Committee (MUHREC) (CF11/
3089-2011001741). All participants provided written in-
formed consent prior to participating in the study.
Results
Seven T1DM participants (5 men, 2 women; mean ± SD
age 37.9 ± 7.0 years) and ten control participants (4 men,
6 women; mean ± SD age 32.9 ± 9.9 years) were included
in the study. All participants regularly ran ≥5 km in a
recreational capacity with a mean weekly run distance of
23 ± 19 km in the T1DM group and 15 ± 7 km in the
control group (p = 0.24). The T1DM group had signifi-
cantly higher BMI, mean BGL and HbA1c than the con-
trol group but was matched for all other variables
(Table 1). No participants had a diagnosis of retinopathy,
nephropathy or neuropathy. Control participants had no
first degree relatives diagnosed with T1DM.
No significant differences were observed between the
groups on day 0 for echo-types I, II, III or IV (p = 0.313,
0.562, 0.492, 0.368 respectively, Fig. 1). Similarly, no
significant difference was observed in day 0 AP ten-
don thickness between the T1DM and control groups
(0.51 ± 0.10 cm, 0.49 ± 0.05 cm respectively, p = 0.368,
Figs. 2 and 3 respectively).
The T1DM group had no significant differences across
days in all four echo-types (I p = 0.368, II p = 1.000,
III p = 1.000 and IV p = 0.174, respectively, Fig. 4).
The control group similarly showed no significant
differences across the four days in all four echo-types
(I p = 0.180, II p = 0.156, III p = 0.651 and IV p = 0.368, re-
spectively, Fig. 5).
Within the control group, baseline (day 0) echo-type I
was not correlated with blood glucose level (Spearman’s
rho = 0.13, p = 0.73) or HbA1c (Spearman’s rho = 0.17,
p = 0.64). Similarly, within the T1DM group, baseline
(day 0) echo-type I was not correlated with blood glu-
cose level (Spearman’s rho = 0.50, p = 0.39) or HbA1c
(Spearman’s rho = −0.10, p = 0.87).
Table 1 Participant Characteristics
Characteristic T1DM Control
(Mean ± SD) (Mean ± SD)
Gender 5 men, 2 women 4 men, 6 women
Age (years) 37.9 ± 7.0 32.9 ± 9.9
Height (cm) 170.9 ± 8.1 171.2 ± 8.2
Body mass (kg) 74.1 ± 10.8 65.7 ± 11.9
BMI 25.4 ± 3.3* 22.2 ± 2.3
Waist circumference (cm) 85.7 ± 10.9 80.0 ± 10.0
Mean blood glucose (mmol/L) 10.1 ± 4.3* 5.1 ± 0.8
HbA1c (%) 8.7 ± 2.6* 5.3 ± 0.4
mmol/mol 71.3 ± 4.7* 34.9 ± 0.4 %
Average run speed (km/h) 10.9 ± 1.7 10.7 ± 1.5
VISA-A score 94.1 ± 9.6 93.9 ± 11.4
Avg run distance per week (km) 22.6 ± 18.9 14.8 ± 6.6
*p-value <0.05
Fig. 1 Echo-types I-IV in T1DM and control group at Day 0
(median ± IQR)
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Discussion
This study measured Achilles tendon response to a
10 km run in individuals with T1DM and control partic-
ipants. The main finding of this study was no significant
change in echopattern across the four days for either
group, which indicates a response was not elicited in the
Achilles tendon by the 10 km run. Both the T1DM and
control groups demonstrated high percentages of echo-
type I, which reflects homogeneity of tendon fibrils
within the tendon matrix [22].
These results differ to previous UTC studies, which
found a transient response in tendons to maximal exer-
cise at day 2 and a return to baseline by day 4 [23, 24].
These studies involved competitive sporting events that
placed the tendon under maximal load, and elicited a re-
sponse in the tendon that was detected using UTC. As
the current study involved a recreational 10 km run ra-
ther than maximal competitive load, participants may
not have maximally loaded their Achilles tendons. Many
participants were completing a moderate number of
kilometres per week, with some participants reporting
they were currently training for a marathon. Therefore,
the capacity of the Achilles tendon to tolerate load may
have been much higher than was achieved during a so-
cial 10 km run. The current study also differed from
previous studies as both men and women were included,
and they were older than the male only participants in-
cluded in the Rosengarten et al. [24] study. While no
Fig. 2 UTC image of a T1DM Achilles tendon in transverse
view at baseline (Day 0). The border of the Achilles tendon is
demarcated by the white line, with the surrounding pixels greyed
out. Echo-types I, II, III and IV are represented as green, blue, red
and black respectively
Fig. 3 UTC image of a control Achilles tendon in transverse
view at baseline (Day 0). The border of the Achilles tendon is
demarcated by the white line, with the surrounding pixels
greyed out. Echo-types I, II, III and IV are represented as green,
blue, red and black respectively
Fig. 4 Echo-types I-IV in the T1DM group at Day 0, 2 and 4 post
10 km run (median ± IQR)
Fig. 5 Echo-types I-IV in the control group at Day 0, 2 and 4 post
10 km run (median ± IQR)
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detectable response was found at 10 km for the T1DM
or control groups, it is unknown whether the T1DM
group would have similar or differing response in their
tendons at maximal load compared to controls.
The study findings suggest T1DM individuals who are
physically active have similar Achilles tendon response
to controls; however tendon response in T1DM individ-
uals who are sedentary is unknown. Achilles tendinopa-
thy commonly affects individuals who live an active
lifestyle, particularly those who are runners, however
sedentary individuals are also at risk of developing the
condition [30, 31]. Further research is required to deter-
mine the tendon response to load among i) sedentary in-
dividuals with T1DM, ii) individuals with T2DM who
typically also have obesity, insulin resistance and ele-
vated lipids [15, 16, 32, 33], and iii) sedentary non-
diabetic individuals [34, 35]. It is important to consider
this because treatment options may vary - for example,
eccentric loading may be the selected treatment option
for recreational athletes with a chronic Achilles tendino-
pathy, however may not be as beneficial in the sedentary
population [35]. Sayana and Maffulli [35] found that less
than 60 % of sedentary individuals had positive effects
from eccentric exercise.
Another finding of the current study was that baseline
(day 0) Achilles tendon structure was the same between
T1DM and control groups. This concurs with several
studies that found DM tendons were similar to controls
or the general population. de Jonge et al. [17] reported
the prevalence of T1DM in the mid-Achilles tendinopa-
thy population was the same as the general Dutch popu-
lation. Similarly, tendon structure of the flexor hallucis
longus tendon on CT imaging showed no significant dif-
ference in tendon thickness between DM and control
participants [36]. However, this study pooled T1/T2DM
data, therefore the influence of T1DM on tendon struc-
ture is unclear.
In contrast, several studies that pooled T1/T2DM data
found a significant increase in Achilles tendon thickness
in DM participants compared to controls on ultrasound
imaging [15, 16]. This finding was consistent across DM
participants without neuropathy, DM participants with
neuropathy and DM participants with neuropathic ulcers
compared to controls [15, 16]. Furthermore, studies that
provide T2DM only data have shown a significant in-
crease in tendon thickness in women but not men [32],
and a significant increase in tendon volume in both men
and women [33].
The interest in investigating T1DM separately to
T2DM comes from the profound differences in the
pathophysiological causes of T1/T2 DM and the resulting
exposure to hyperglycaemia. While chronic hyperglycaemia
has been hypothesised to be the cause of pathological
changes in tendons [12, 13], there are characteristics
specific to T2DM that may predispose tendons to patho-
logical changes. These characteristics include insulin resist-
ance [37], elevated lipids [38, 39] and elevated adiposity
[40], all of which are associated with T2DM but not com-
monly with T1DM. Another difference between T1DM and
T2DM is time to diagnosis; T1DM is rapidly diagnosed due
to severity of symptoms, whereas T2DM may have a long
asymptomatic duration before diagnosis [1]. Interestingly,
the years prior to T2DM diagnosis are associated with
higher medical costs [41] and increased incidence of mus-
culoskeletal conditions such as carpal tunnel syndrome
[42]. Based on these differences, it is essential that future
research report T1DM and T2DM data separately.
As HbA1c has been used to predict likelihood of de-
veloping diabetic complications such as retinopathy, ne-
phropathy and neuropathy [6, 7], we analysed whether
echo-type I (day 0) was correlated with HbA1c in the
T1DM group. Within the T1DM group baseline (day 0)
echo-type I was not correlated with blood glucose level
(Spearman’s rho = 0.50, p = 0.39) or HbA1c (Spearman’s
rho = −0.10, p = 0.87), however it is difficult to provide a
definitive answer with a limited sample size.
Maintaining a HbA1c <7 % (53 mmol/mol) indicates
good T1DM control and can decrease the likelihood of
developing diabetic complications [6, 7]. However, a
retrospective cohort study of 386 participants identified
that only 3.4 % of T1DM individuals actually achieve this
target HbA1c level, and the average T1DM HbA1c is
9.2 % [43]. Our T1DM group had a HbA1c of 8.7 %
(71.3 mmol/mol) which is higher than the recommended
value but below the HbA1c level in other studies. A
population based study found that >50 % T1DM individ-
uals will develop detectable diabetic complications on
average 12 years after diagnosis of the disease, despite
modern advancement with insulin treatment [44]. Our
T1DM group were diagnosed 13 ± 12 years ago and yet
none had a diagnosis of retinopathy, neuropathy or ne-
phropathy. This complication rate is much lower than
other studies with similar populations. These observa-
tions indicate we studied a highly selected sub-group of
T1DM individuals who have good T1DM management,
are well organised, and conscientious enough to run on
a regular basis and volunteer for research projects.
It is also of interest to note that the T1DM group
demonstrated larger variability in echopattern (larger
IQR) compared to the control group, particularly notice-
able for echo type I and II at day-2 and day-4 post run.
We can speculate that this might reflect an underlying dif-
ference in the way that the Achilles tendon of individuals
with T1DM responds to a bolus of load. For example, it is
known that hyperglycaemia reduces proteoglycan levels
and increases matrix metalloproteinase levels in cultured
tendon cells [45, 46]. Whether these cell-culture findings
translate to clinical observations remains unknown at
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present. The variability in echo type may also reflect dif-
ferences in participant behaviour after the run, for ex-
ample, it is unknown whether all participants refrained
from physical activity for 4-days after the run as
requested.
Limitations
Limitations of this preliminary study were the small
sample size and a target population of T1DM individuals
with a low BMI who regularly ran in a recreational cap-
acity. Therefore, the findings of this study cannot at
present be generalised to the wider T1DM population.
Furthermore, although non-significant, the T1DM group
ran on average longer distances per week than control
group, which may have impacted on the results of this
study. Another limitation of the study was the non-
competitive nature of the 10 km run, rather than a max-
imal competitive load.
Due to the low participant numbers, bivariate correla-
tions were kept to a minimum. We decided to focus on
BGL and HbA1c, as these were significantly different
between the T1DM and control group and are key mea-
sures of T1DM control. Future studies should consider
adjusting the data for covariates, such as duration of
DM and HbA1c.
Perspective
As physical activity is a key component of long-term
metabolic control in T1DM [19], it is important to know
how the Achilles tendon responds to load. In doing so, a
better understanding and improved exercise prescription
and injury management in the T1DM community can be
achieved. Our findings suggest that individuals with
T1DM who are regularly physically active do not have
pathological changes to their Achilles tendons, in con-
trast to prior findings among individuals with T2DM
[14]. Further research is required to determine whether
our findings are unique to T1DM individuals who are
regularly physically active, or whether they also apply to
sedentary individuals with T1DM.
Conclusion
We found that Achilles tendon baseline structure and
response to a 10 km run over 4-days was the same in
controls and T1DM individuals. The contrast with previ-
ous studies in T2DM most likely reflects the profound
differences between the pathophysiology of T1DM and
T2DM. This contrast strengthens the argument that
tendon health of individuals with T1DM and T2DM
should be studied separately.
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